Thursday, January 4, 2018

Neuropore Therapies Gets Second Grant From Michael J. Fox Foundation

San Diego-based biopharmaceuticals developer Neuropore Therapies, which is developing biopharmaceuticals to treat Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorders, has received a second grant from the Michael J. Fox Foundation (MJFF). According to Neuropore, the grant will go to support its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson's disease and other neurodegenerative disorders. Size of the new grant was not announced. Neuropore's first grant from the MJFF came almost exactly a year ago.